Abstract LB432: Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model
Bibliographic record
Abstract
Abstract BOLD-100 is a first-in-class, ruthenium-based anticancer agent in Phase 2 clinical development for advanced gastrointestinal (GI) cancers in combination with FOLFOX. Clinical results have shown that BOLD-100 combined with FOLFOX improves overall survival (OS) and progression-free survival (PFS) in patients with advanced colon, gastric, and bile duct cancers. Emerging clinical evidence indicates a very well tolerated safety profile for BOLD-100 in combination with FOLFOX. While FOLFOX is a first- or second-line standard-of-care therapy for GI cancers, its clinical utility is limited by the induction of acute and chronic peripheral neuropathies. Notably, in clinical trial BOLD-100-001 (NCT04421820), an unexpected reduction in oxaliplatin-induced peripheral neuropathy (OIPN) was observed. In patients treated with BOLD-100 and FOLFOX, any-grade neuropathy was reduced compared to benchmark FOLFOX-alone patients: mCRC (14% vs. 53%), BTC (36% vs. 67%), and GC (19% vs. 63%). However, translational and preclinical investigations into the neuroprotective effects of BOLD-100 are necessary. To assess BOLD-100’s neuroprotective effects in an in-vivo model, Sprague-Dawley (SD) rats received intraperitoneal low-dose oxaliplatin (0.5 mg/kg) or high-dose oxaliplatin (1.5 mg/kg) twice weekly until Day 17. Concurrently, BOLD-100 (40 mg/kg) or vehicle (10 mL/kg) was administered via slow IV bolus (∼30 seconds) twice weekly. Cold allodynia was measured using the acetone spray test at baseline (Day -1) and 0.5 hours post-oxaliplatin administration on each dosing day. Rats treated only with oxaliplatin developed significant cold allodynia by Day 7 (high dose) and Day 10 (low dose), whereas animals co-treated with BOLD-100 substantially prevented the development of peripheral neuropathy at both oxaliplatin doses. In the high-dose model, significant attenuation of OIPN was observed as early as Day 7 (p = 0.02), with highly significant reductions from Day 10 (p = 0.0009) to Day 21 (p < 0.000001). In the low-dose model, a complete attenuation of OIPN was observed from Day 10 (p = 0.01) to Day 21 (p = 0.00007). To elucidate possible mechanisms, we used plasma samples from patients in clinical trial BOLD-100-001, we observed a strong induction of multiple cytokines relevant to neuroprotective effects. Importantly, patients who developed neurotoxicity-related adverse events during the study appeared to have a reduced capacity to induce these cytokines after BOLD-100 treatment. Collectively, these findings provide strong evidence that BOLD-100 not only enhances oxaliplatin-based therapy in GI malignancies but also improves its clinical utility by markedly reducing OIPN. Ongoing clinical studies are evaluating BOLD-100’s neuroprotective benefits and its potential to enhance the therapeutic index of standard-of-care regimens for advanced GI cancers. Citation Format: Ashish Kumar, Brian Park, Malcolm Snow, Russell McAllister, Jim Pankovich, Mark Bazett. Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB432.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".